Gateway drug effect

Last updated

The gateway drug effect (alternatively, stepping-stone theory, escalation hypothesis, or progression hypothesis) is a comprehensive catchphrase for the often observed effect that the use of a psychoactive substance is coupled to an increased probability of the use of further substances. Possible reasons for the connection include environmental influence, impulsive people seeking both soft and hard drugs (meaning people who use one drug are likely to use another drug due to personality and that it's not the initial drug that leads to the use of another drug), [1] alterations in the brain due to earlier substance exposure, as well as similar attitudes of people who use different substances, and therefore experience a "common liability to addiction". [2] In 2020, the National Institute on Drug Abuse released a research report which supported allegations that marijuana is a "gateway" [3] to more dangerous substance use; one of the peer-reviewed papers cited in the report claims that while "some studies have found that use of legal drugs or cannabis are not a requirement for the progression to other illicit drugs [...] most studies have supported the "gateway sequence"." [4] However, a 2018 literature review conducted by the National Institute of Justice, which analyzed 23 peer-reviewed research studies, concluded "that existing statistical research and analysis relevant to the "gateway" hypothesis has produced mixed results", [5] and that "no causal link between cannabis use and the use of other illicit drugs can be claimed at this time." [5]

Contents

History

While the phrase gateway drug was first popularized by anti-drug activists such as Robert DuPont in the 1980s, the underlying ideas had already been discussed since the 1930s by using the phrases stepping-stone theory, escalation hypothesis, or progression hypothesis. [6] [7]

The scientific and political discussion has intensified since 1975 after the publications of several longitudinal studies by Denise Kandel and others. [8] [9] [10]

In 2019, a research report by the National Institute on Drug Abuse determined that marijuana use is "likely to precede use of other licit and illicit substances", and cited a longitudinal study in which "adults who reported marijuana use during the first wave of the survey were more likely than adults who did not use marijuana to develop an alcohol use disorder within 3 years; people who used marijuana and already had an alcohol use disorder at the outset were at greater risk of their alcohol use disorder worsening." [3] They further claimed that marijuana use "is also linked to other substance use disorders including nicotine addiction." [3] While stating that their "findings are consistent with the idea of marijuana as a "gateway drug"", [3] they conceded that "the majority of people who use marijuana do not go on to use other, "harder" substances", [3] and that "cross-sensitization is not unique to marijuana. Alcohol and nicotine also prime the brain for a heightened response to other drugs and are, like marijuana, also typically used before a person progresses to other, more harmful substances." [3]

On the other hand, the 2018 report issued by the National Institute of Justice states "that the current state of research on this issue is limited, and the studies that have been conducted suffer from difficulties in collecting information and applying the findings to a larger population. The report further notes that although many of the reviewed studies found statistically significant associations between cannabis use and the users' later use of other illicit drugs, there is currently no conclusive evidence that cannabis use caused the later use of harder illicit drugs." [5]

Sequence of first-time use

General concept

The concept of gateway drug is based on observations that the sequence of first-time use of different drugs is not random but shows trends. On the basis of established techniques of longitudinal studies such trends can be described precisely in terms of statistical probability. As to the interpretation of the observed trends, it is important to note the difference between sequence and causation. Both may – but need not – be coupled, a question which is subject of further research, e.g., by physiological experiments. [11]

From a sample of 6,624 people who had not used other illegal drugs before their cannabis consumption the overall probability of later use of other illegal drugs was estimated to be 44.7%. Subgroup analyses showed that personal and social conditions, such as gender, age, marital status, mental disorders, family history of substance use, overlapping illegal drug distribution channels, alcohol use disorder, nicotine dependence, ethnicity, urbanicity, and educational attainment influenced the height of probability. [12] [13]

A study of drug use of 14,577 U.S. 12th graders showed that alcohol consumption was associated with an increased probability of later use of tobacco, cannabis, and other illegal drugs. Adolescents who smoked cigarettes before age 15 were up to 80 times more likely to use illegal drugs. [14] Studies indicate vaping serves as a gateway to traditional cigarettes and cannabis use. [15]

Large-scale longitudinal studies in the U.K. and New Zealand from 2015 and 2017 showed an association between cannabis use and an increased probability of later disorders in the use of other drugs. [16] [17] [18]

Students who regularly consume caffeinated energy drinks have a greater risk of alcohol use disorder, cocaine use and misuse of prescription stimulants. The elevated risk remains after accounting for prior substance use and other risk factors. [19]

A meta-analysis about the use of e-cigarettes of 2018 said that "Because the term 'gateway' has historically been used in colloquial, non-scientific settings and lacks a clear definition, it is not used in this report". [20]

Associations aside from first-time use

The role of cannabis use in regard to alcohol use and Alcohol Use Disorder (AUD) is still not fully understood. Some studies suggest better alcohol treatment completion for those who use cannabis, while other studies find the opposite. [21] A 2016 review of 39 studies which examined the relation between cannabis use and alcohol use found that 16 studies support the idea that cannabis and alcohol are substitutes for each other, 10 studies found that they are complements, 12 found that they are neither complementary nor substitutes, and one found that they are both. [22]

A study involving self-reported data from a sample of 27,461 people examined the relationship of cannabis use and AUD. These respondents had no prior diagnosis of AUD. Of the 27,461 people, 160 had reported cannabis use within the past year. At the end of a three-year period, it found that those who had previously reported cannabis use were associated with a five times greater odds of being diagnosed with AUD than those who had not. After adjustment for select confounders (age, race, marital status, income, and education), these odds were reduced to two times greater risk. Another sample of self-reported data from 2,121 persons included only those who had already been diagnosed with AUD. In this sample, it was found that those who had reported cannabis use in the past year (416 people) were associated with 1.7 greater odds of AUD persistence three years later. After adjustment for the same confounders as before, these odds were reduced to 1.3. [23] [24]

Causes

Because a sequence of first-time use can only indicate the possibility – but not the fact – of an underlying causal relation, different theories concerning the observed trends were developed. The scientific discussion (state of 2016) is dominated by two concepts, which appear to cover almost all possible causal connections if appropriately combined. These are the theories of biological alterations in the brain due to an earlier drug use and the theory of similar attitudes across different drugs. [2] [25] [26]

Alterations in the brain

Adolescent rats repeatedly injected with tetrahydrocannabinol increased the self-administration of heroin (results based on 11 male rats [27] and >50 male rats [28] ), morphine (study based on 12 male rats) [29] and also nicotine (34 rats). [30] There were direct indications that the alteration consisted of lasting anatomical changes in the reward system of the brain. [27] [28] Because the reward system is anatomically, physiologically, and functionally almost identical across the class of mammals, [31] [32] [33] the importance of the findings from animal studies for the reward system in the human brain in relation to the liability to the use of further drugs has been pointed out in several reviews. [34] [35] [36] [37]

In mice, nicotine increased the probability of later consumption of cocaine, and the experiments permitted concrete conclusions on the underlying molecular biological alteration in the brain. [38] The biological changes in mice correspond to the epidemiological observations in humans that nicotine consumption is coupled to an increased probability of later use of cannabis and cocaine, [39] as well as other drugs. [40]

In rats, alcohol increased the probability of later addiction to cocaine and again relevant alterations in the reward system were identified. [41] [42] These observations thus correspond to the epidemiological findings that the consumption of alcohol in humans is coupled to a later increased risk of a transition from cocaine use to cocaine addiction. [43] [44]

Controlled animal and human studies showed that caffeine (energy drinks) in combination with alcohol increased the craving for more alcohol more strongly than alcohol alone. [45] These findings correspond to epidemiological data that people who consume energy drinks generally showed an increased tendency to take alcohol and other substances. [46] [19]

Personal, social and genetic factors

According to the concept of similar attitudes across different drugs (common liability to addiction), a number of personal, social, genetic and environmental factors can lead to a generally increased interest in various drugs. The sequence of first-time use would then depend on these factors. [2] [47] Violations of the typical sequence of first-time drug usage give credit to this theory. For example, in Japan, where cannabis use is uncommon, 83.2% of the people who used illicit substances did not use cannabis first. [2] The concept received additional support from a large-scale genetic analysis that showed a genetic basis for the connection of the prevalence of cigarette smoking and cannabis use during the life of a person. [48]

The results of a twin study presented indications that familial genetic and familial environmental factors do not fully explain these associations, and are possibly only relevant for sequences of some drugs. In 219 same-sex Dutch identical and non-identical twin pairs, one co-twin had reported cannabis use before the age of 18 whereas the other had not. In the cannabis group the lifetime prevalence of later reported use of party drugs was four times higher and the lifetime prevalence of later reported use of hard drugs was seven times higher than in the non-cannabis group. The authors concluded that at least family influences – both genetic and social ones – could not explain the differences. The study noted that, besides a potential causal role of cannabis use, non shared environment factors could play a role in the association such as differing peer affiliations that preceded the cannabis use. [49] [50]

Another twin study (of 510 same sex twin pairs) also examined the association of earlier cannabis use and later hard drug use. Like other studies it examined later drug use differences between siblings where one sibling had used cannabis early and the other had not. The study examined identical twins (who share approximately 100% of their genes) and non-identical twins (who share approximately 50% of their genes) separately and adjusted for additional confounders such as peer drug use. It found, after confounder adjustment, that the associations with later hard drug use existed only for non-identical twins. This suggests a significant genetic factor in the likelihood of later hard drug usage. The study suggested that a causal role of cannabis use in later hard drug usage is minimal, if it exists at all, and that cannabis use and hard drug use share the same influencing factors such as genetics and environment. [51] [50]

See also

Related Research Articles

<span class="mw-page-title-main">Recreational drug use</span> Use of drugs with the primary intention to alter the state of consciousness

Recreational drug use is the use of one or more psychoactive drugs to induce an altered state of consciousness, either for pleasure or for some other casual purpose or pastime. When a psychoactive drug enters the user's body, it induces an intoxicating effect. Recreational drugs are commonly divided into three categories: depressants, stimulants, and hallucinogens.

<span class="mw-page-title-main">Substance abuse</span> Harmful use of drugs

Substance abuse, also known as drug abuse, is the use of a drug in amounts or by methods that are harmful to the individual or others. It is a form of substance-related disorder. Differing definitions of drug abuse are used in public health, medical, and criminal justice contexts. In some cases, criminal or anti-social behavior occurs when the person is under the influence of a drug, and long-term personality changes in individuals may also occur. In addition to possible physical, social, and psychological harm, the use of some drugs may also lead to criminal penalties, although these vary widely depending on the local jurisdiction.

Self-medication, sometime called do-it-yourself (DIY) medicine, is a human behavior in which an individual uses a substance or any exogenous influence to self-administer treatment for physical or psychological conditions, for example headaches or fatigue.

<span class="mw-page-title-main">Cannabis (drug)</span> Psychoactive drug from the cannabis plant

Cannabis, also known as marijuana or weed, among other names, is a non-chemically uniform drug from the cannabis plant. Native to Central or South Asia, the cannabis plant has been used as a drug for both recreational and entheogenic purposes and in various traditional medicines for centuries. Tetrahydrocannabinol (THC) is the main psychoactive component of cannabis, which is one of the 483 known compounds in the plant, including at least 65 other cannabinoids, such as cannabidiol (CBD). Cannabis can be used by smoking, vaporizing, within food, or as an extract.

Substance dependence, also known as drug dependence, is a biopsychological situation whereby an individual's functionality is dependent on the necessitated re-consumption of a psychoactive substance because of an adaptive state that has developed within the individual from psychoactive substance consumption that results in the experience of withdrawal and that necessitates the re-consumption of the drug. A drug addiction, a distinct concept from substance dependence, is defined as compulsive, out-of-control drug use, despite negative consequences. An addictive drug is a drug which is both rewarding and reinforcing. ΔFosB, a gene transcription factor, is now known to be a critical component and common factor in the development of virtually all forms of behavioral and drug addictions, but not dependence.

<span class="mw-page-title-main">Tobacco and other drugs</span> Association between tobacco and other drug use

An association between tobacco and other drug use has been well established. The nature of this association remains unclear. The two main theories, which are not mutually exclusive, are the phenotypic causation (gateway) model and the correlated liabilities model. The causation model argues that smoking is a primary influence on future drug use, while the correlated liabilities model argues that smoking and other drug use are predicated on genetic or environmental factors.

<span class="mw-page-title-main">Polysubstance dependence</span> A type of substance use disorder

Polysubstance dependence refers to a type of substance use disorder in which an individual uses at least three different classes of substances indiscriminately and does not have a favorite substance that qualifies for dependence on its own. Although any combination of three substances can be used, studies have shown that alcohol is commonly used with another substance. One study on polysubstance use categorized participants who used multiple substances according to their substance of preference. The results of a longitudinal study on substance use led the researchers to observe that excessively using or relying on one substance increased the probability of excessively using or relying on another substance.

<span class="mw-page-title-main">Long-term effects of cannabis</span>

The long-term effects of cannabis have been the subject of ongoing debate. Given that the use of cannabis is illegal in most countries, clinical research presents a challenge and there is limited evidence from which to draw conclusions. In 2017, the U.S. National Academies of Sciences, Engineering, and Medicine issued a report summarizing much of the published literature on health effects of cannabis, into categories regarded as conclusive, substantial, moderate, limited and of no or insufficient evidence to support an association with a particular outcome.

<span class="mw-page-title-main">Substance use disorder</span> Continual use of drugs (including alcohol) despite detrimental consequences

Substance use disorder (SUD) is the persistent use of drugs despite the substantial harm and adverse consequences to one's own self and others, as a result of their use. In perspective, the effects of the wrong use of substances that are capable of causing harm to the user or others, have been extensively described in different studies using a variety of terms such as substance use problems, problematic drugs or alcohol use, and substance use disorder.The National Institute of Mental Health (NIMH) states that "Substance use disorder (SUD) is a treatable mental disorder that affects a person's brain and behavior, leading to their inability to control their use of substances like legal or illegal drugs, alcohol, or medications. Symptoms can be moderate to severe, with addiction being the most severe form of SUD".Substance use disorders (SUD) are considered to be a serious mental illness that fluctuates with the age that symptoms first start appearing in an individual, the time during which it exists and the type of substance that is used. It is not uncommon for those who have SUD to also have other mental health disorders. Substance use disorders are characterized by an array of mental/emotional, physical, and behavioral problems such as chronic guilt; an inability to reduce or stop consuming the substance(s) despite repeated attempts; operating vehicles while intoxicated; and physiological withdrawal symptoms. Drug classes that are commonly involved in SUD include: alcohol (alcoholism); cannabis; opioids; stimulants such as nicotine (including tobacco), cocaine and amphetamines; benzodiazepines; barbiturates; and other substances.

<span class="mw-page-title-main">Addiction</span> Disorder resulting in compulsive behaviours

Addiction is a neuropsychological disorder characterized by a persistent and intense urge to use a drug or engage in a behavior that produces natural reward, despite substantial harm and other negative consequences. Repetitive drug use often alters brain function in ways that perpetuate craving, and weakens self-control. This phenomenon – drugs reshaping brain function – has led to an understanding of addiction as a brain disorder with a complex variety of psychosocial as well as neurobiological factors that are implicated in addiction's development.

<span class="mw-page-title-main">Cannabis use disorder</span> Continued use of cannabis despite clinically significant impairment

Cannabis use disorder (CUD), also known as cannabis addiction or marijuana addiction, is a psychiatric disorder defined in the fifth revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and ICD-10 as the continued use of cannabis despite clinically significant impairment.

<span class="mw-page-title-main">Psychoactive drug</span> Chemical substance that alters nervous system function

A psychoactive drug, mind-altering drug, or consciousness-altering drug is a chemical substance that changes brain function and results in alterations in perception, mood, consciousness, cognition, or behavior. The term psychotropic drug is often used interchangeably, while some sources present narrower definitions. These substances may be used medically; recreationally; to purposefully improve performance or alter one's consciousness; as entheogens for ritual, spiritual, or shamanic purposes; or for research, including psychedelic therapy. Some categories of psychoactive drugs, which have therapeutic value, are prescribed by physicians and other healthcare practitioners. Examples include anesthetics, analgesics, anticonvulsant and antiparkinsonian drugs as well as medications used to treat neuropsychiatric disorders, such as antidepressants, anxiolytics, antipsychotics, and stimulant medications. Some psychoactive substances may be used in the detoxification and rehabilitation programs for persons dependent on or addicted to other psychoactive drugs.

Personality theories of addiction are psychological models that associate personality traits or modes of thinking with an individual's proclivity for developing an addiction. Models of addiction risk that have been proposed in psychology literature include an affect dysregulation model of positive and negative psychological affects, the reinforcement sensitivity theory model of impulsiveness and behavioral inhibition, and an impulsivity model of reward sensitization and impulsiveness.

<span class="mw-page-title-main">Denise Kandel</span> American medical sociologist and epidemiologist

Denise Kandel is an American medical sociologist and epidemiologist, Professor of Sociomedical Sciences and Psychiatry at Columbia University and Head of the Department of Epidemiology of Substance Abuse at the New York State Psychiatric Institute. She is known for her epidemiological longitudinal studies on the sequence of first-time use of various legal and illegal drugs, carried out beginning in the 1970s and continuing until at least 2016.

<span class="mw-page-title-main">Cannabis in Turkey</span>

Cannabis is illegal in Turkey for recreational use, but allowed for limited medical and scientific purposes. The Turkish term for cannabis is kenevir.

<i>Licit and Illicit Drugs</i> 1972 book by Edward M. Brecher

Licit and Illicit Drugs: The Consumers Union Report on Narcotics, Stimulants, Depressants, Inhalants, Hallucinogens, and Marijuana–including Caffeine, Nicotine and Alcohol is a 1972 book on recreational drug use by medical writer Edward M. Brecher and the editors of Consumer Reports.

Evolutionary models of drug use seek to explain human drug usage from the perspective of evolutionary fitness. Plants for instance, may provide fitness benefits by relieving pain. Proponents of this model of drug use suggest that the consumption of pharmacological substances for medicinal purposes evolved in the backdrop of human-plant coevolution as a means of self-medication. Humans thus learned to ignore the cues of plant toxicity because ingesting the bioactive compounds of plants in small amounts was therapeutic.

Discrimination against people with substance use disorders is a form of discrimination against people with this disease. In the United States, people with substance use disorders are often blamed for their disease, which is often seen as a moral failing, due to a lack of public understanding about substance use disorders being diseases of the brain with 40-60% heritability. People with substance use disorders are likely to be stigmatized, whether in society or healthcare.

Exposure to nicotine, from conventional or electronic cigarettes during adolescence can impair the developing human brain. E-cigarette use is recognized as a substantial threat to adolescent behavioral health. The use of tobacco products, no matter what type, is almost always started and established during adolescence when the developing brain is most vulnerable to nicotine addiction. Young people's brains build synapses faster than adult brains. Because addiction is a form of learning, adolescents can get addicted more easily than adults. The nicotine in e-cigarettes can also prime the adolescent brain for addiction to other drugs such as cocaine. Exposure to nicotine and its great risk of developing an addiction, are areas of significant concern.

<span class="mw-page-title-main">Prescription drug addiction</span> Medical condition

Prescription drug addiction is the chronic, repeated use of a prescription drug in ways other than prescribed for, including using someone else’s prescription. A prescription drug is a pharmaceutical drug that may not be dispensed without a legal medical prescription. Drugs in this category are supervised due to their potential for misuse and substance use disorder. The classes of medications most commonly abused are opioids, central nervous system (CNS) depressants and central nervous stimulants. In particular, prescription opioid is most commonly abused in the form of prescription analgesics.

References

  1. ↑ "Gateway Drug Hypothesis | Drug Policy Facts".
  2. 1 2 3 4 Vanyukov MM, Tarter RE, Kirillova GP, et al. (June 2012). "Common liability to addiction and "gateway hypothesis": theoretical, empirical and evolutionary perspective". Drug Alcohol Depend (Review). 123 (Suppl 1): S3–17. doi:10.1016/j.drugalcdep.2011.12.018. PMC   3600369 . PMID   22261179.
  3. 1 2 3 4 5 6 "Marijuana Research Report:Is marijuana a gateway drug?". National Institute on Drug Abuse. July 2020. Retrieved November 7, 2020.
  4. ↑ Secades-Villa R, Garcia-Rodríguez O, Jin CJ, Wang S, Blanco C (2015). "Probability and predictors of the cannabis gateway effect: a national study". Int J Drug Policy. 26 (2): 135–42. doi:10.1016/j.drugpo.2014.07.011. PMC   4291295 . PMID   25168081.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  5. 1 2 3 "Is Cannabis a Gateway Drug? Key Findings and Literature Review". National Institute of Justice. Retrieved 2022-04-01.
  6. ↑ D. B. Kandel (Ed.): Stages and Pathways of Drug Involvement: Examining the Gateway Hypothesis, Cambridge University Press, 2002, ISBN   978-0-521-78969-1, p. 4.
  7. ↑ Erich Goode: Marijuana use and the progression to dangarous drugs, in: Miller, Loren, ed. (1974). Marijuana Effects on Human Behavior. Burlington: Elsevier Science. pp. 303–338. ISBN   978-1-4832-5811-9.
  8. ↑ Kandel, D (1975). "Stages in adolescent involvement in drug use". Science. 190 (4217): 912–914. Bibcode:1975Sci...190..912K. doi:10.1126/science.1188374. hdl: 10983/25298 . PMID   1188374. S2CID   30124614.
  9. ↑ Yamaguchi, K; Kandel, D. B. (1984). "Patterns of drug use from adolescence to young adulthood: II. Sequences of progression". American Journal of Public Health. 74 (7): 668–672. doi:10.2105/ajph.74.7.668. PMC   1651663 . PMID   6742252.
  10. ↑ Kandel, D; Yamaguchi, K (1993). "From beer to crack: Developmental patterns of drug involvement". American Journal of Public Health. 83 (6): 851–855. doi:10.2105/ajph.83.6.851. PMC   1694748 . PMID   8498623.
  11. ↑ D. B. Kandel (Ed.): Stages and Pathways of Drug Involvement: Examining the Gateway Hypothesis, Cambridge University Press, 2002, ISBN   978-0-521-78969-1, pp. 3-10.
  12. ↑ Secades-Villa, R; Garcia-Rodríguez, O; Jin, C. J.; Wang, S; Blanco, C (2015). "Probability and predictors of the cannabis gateway effect: A national study". International Journal of Drug Policy. 26 (2): 135–142. doi:10.1016/j.drugpo.2014.07.011. PMC   4291295 . PMID   25168081.
  13. ↑ Kluger B, Triolo P, Jones W, Jankovic J (2015). "The therapeutic potential of cannabinoids for movement disorders". Movement Disorders. 30 (3): 313–27. doi:10.1002/mds.26142. PMC   4357541 . PMID   25649017.
  14. ↑ Kirby, T; Barry, A. E. (2012). "Alcohol as a gateway drug: A study of US 12th graders" (PDF). Journal of School Health. 82 (8): 371–9. doi:10.1111/j.1746-1561.2012.00712.x. PMID   22712674. Archived from the original (PDF) on 2016-06-04. Retrieved 2016-05-26.
  15. ↑ Fadus, Matthew C.; Smith, Tracy T.; Squeglia, Lindsay M. (2019). "The rise of e-cigarettes, pod mod devices, and JUUL among youth: Factors influencing use, health implications, and downstream effects". Drug and Alcohol Dependence. 201: 85–93. doi:10.1016/j.drugalcdep.2019.04.011. ISSN   0376-8716. PMC   7183384 . PMID   31200279.
  16. ↑ Courtney KE, Mejia MH, Jacobus J (2017). "Longitudinal Studies on the Etiology of Cannabis Use Disorder: A Review". Current Addiction Reports. 4 (2): 43–52. doi:10.1007/s40429-017-0133-3. PMC   5644349 . PMID   29057198.
  17. ↑ Badiani A, Boden JM, De Pirro S, Fergusson DM, Horwood LJ, Harold GT (2015). "Tobacco smoking and cannabis use in a longitudinal birth cohort: evidence of reciprocal causal relationships". Drug and Alcohol Dependence. 150: 69–76. doi:10.1016/j.drugalcdep.2015.02.015. hdl: 10523/10359 . PMID   25759089.
  18. ↑ Taylor M, Collin SM, Munafò MR, MacLeod J, Hickman M, Heron J (2017). "Patterns of cannabis use during adolescence and their association with harmful substance use behaviour: findings from a UK birth cohort". Journal of Epidemiology and Community Health. 71 (8): 764–770. doi:10.1136/jech-2016-208503. PMC   5537531 . PMID   28592420.
  19. 1 2 "Energy drinks and risk to future substance use". www.drugabuse.gov. National Institute on Drug Abuse. 8 August 2017. Archived from the original on 18 February 2020. Retrieved 29 March 2019.
  20. ↑ National Academies of Sciences, Engineering, and Medicine (2018). Stratton, Kathleen; Kwan, Leslie Y; Eaton, David L (eds.). Public Health Consequences of E-Cigarettes. National Academies Press. p. 496. doi:10.17226/24952. ISBN   978-0-309-46834-3. PMID   29894118.{{cite book}}: CS1 maint: multiple names: authors list (link)
  21. ↑ Subbaraman, MS (2014). "Can cannabis be considered a substitute medication for alcohol?". Alcohol and Alcoholism. 49 (3): 292–8. doi:10.1093/alcalc/agt182. PMC   3992908 . PMID   24402247.
  22. ↑ Subbaraman, MS (18 September 2016). "Substitution and Complementarity of Alcohol and Cannabis: A Review of the Literature". Substance Use & Misuse. 51 (11): 1399–414. doi:10.3109/10826084.2016.1170145. PMC   4993200 . PMID   27249324.
  23. ↑ Yurasek Ali M., Aston Elizabeth R., Metrik Jane (2017). "Co-use of Alcohol and Cannabis: A Review". Current Addiction Reports. 4 (2): 184–193. doi:10.1007/s40429-017-0149-8. PMC   7363401 . PMID   32670740.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  24. ↑ Weinberger, A. H.; Platt, J; Goodwin, R. D. (2016). "Is cannabis use associated with an increased risk of onset and persistence of alcohol use disorders? A three-year prospective study among adults in the United States". Drug and Alcohol Dependence. 161: 363–7. doi:10.1016/j.drugalcdep.2016.01.014. PMC   5028105 . PMID   26875671.
  25. ↑ Morral, A. R.; McCaffrey, D. F.; Paddock, S. M. (2002). "Reassessing the marijuana gateway effect". Addiction. 97 (12): 1493–1504. doi:10.1046/j.1360-0443.2002.00280.x. PMID   12472629. S2CID   2833456. (Review).
  26. ↑ Fergusson, D. M.; Boden, J. M.; Horwood, L. J. (2006). "Cannabis use and other illicit drug use: Testing the cannabis gateway hypothesis". Addiction. 101 (4): 556–569. doi:10.1111/j.1360-0443.2005.01322.x. PMID   16548935.
  27. 1 2 Ellgren, M; Spano, S. M.; Hurd, Y. L. (2007). "Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats". Neuropsychopharmacology. 32 (3): 607–615. doi: 10.1038/sj.npp.1301127 . PMID   16823391.
  28. 1 2 Tomasiewicz HC, Jacobs MM, Wilkinson MB, Wilson SP, Nestler EJ, Hurd YL (2012). "Proenkephalin mediates the enduring effects of adolescent cannabis exposure associated with adult opiate vulnerability". Biol Psychiatry. 72 (10): 803–10. doi:10.1016/j.biopsych.2012.04.026. PMC   3440551 . PMID   22683090.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  29. ↑ Cadoni, C; Pisanu, A; Solinas, M; Acquas, E; Di Chiara, G (2001). "Behavioural sensitization after repeated exposure to Delta 9-tetrahydrocannabinol and cross-sensitization with morphine". Psychopharmacology. 158 (3): 259–266. doi:10.1007/s002130100875. PMID   11713615. S2CID   24008118.
  30. ↑ Panlilio, L. V.; Zanettini, C; Barnes, C; Solinas, M; Goldberg, S. R. (2013). "Prior Exposure to THC Increases the Addictive Effects of Nicotine in Rats". Neuropsychopharmacology. 38 (7): 1198–1208. doi:10.1038/npp.2013.16. PMC   3656362 . PMID   23314220.
  31. ↑ O'Connell LA, Hofmann HA (2011). "The vertebrate mesolimbic reward system and social behavior network: a comparative synthesis". J Comp Neurol. 519 (18): 3599–639. doi: 10.1002/cne.22735 . PMID   21800319. S2CID   34009440.
  32. ↑ Alcaro A, Panksepp J (2011). "The SEEKING mind: primal neuro-affective substrates for appetitive incentive states and their pathological dynamics in addictions and depression". Neurosci Biobehav Rev. 35 (9): 1805–20. doi:10.1016/j.neubiorev.2011.03.002. PMID   21396397. S2CID   6613696.
  33. ↑ Panksepp J (2011). "The basic emotional circuits of mammalian brains: do animals have affective lives?" (PDF). Neurosci Biobehav Rev. 35 (9): 1791–804. doi:10.1016/j.neubiorev.2011.08.003. PMID   21872619. S2CID   207089299.
  34. ↑ Panlilio LV, Justinova Z (2018). "Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure". Neuropsychopharmacology. 43 (1): 116–141. doi:10.1038/npp.2017.193. PMC   5719102 . PMID   28845848.
  35. ↑ Parsons LH, Hurd YL (2015). "Endocannabinoid signalling in reward and addiction". Nature Reviews. Neuroscience. 16 (10): 579–94. doi:10.1038/nrn4004. PMC   4652927 . PMID   26373473. (Review).
  36. ↑ Covey DP, Wenzel JM, Cheer JF (2015). "Cannabinoid modulation of drug reward and the implications of marijuana legalization". Brain Research. 1628 (Pt A): 233–43. doi:10.1016/j.brainres.2014.11.034. PMC   4442758 . PMID   25463025., PDF (Review).
  37. ↑ Renard J, Rushlow WJ, Laviolette SR (2016). "What Can Rats Tell Us about Adolescent Cannabis Exposure? Insights from Preclinical Research". Canadian Journal of Psychiatry. 61 (6): 328–34. doi:10.1177/0706743716645288. PMC   4872245 . PMID   27254841., PDF (Review).
  38. ↑ E. R. Kandel; D. B. Kandel (2014). "A Molecular Basis for Nicotine as a Gateway Drug". New England Journal of Medicine. 371 (10): 932–943. doi:10.1056/NEJMsa1405092. PMC   4353486 . PMID   25184865.
  39. ↑ Keyes, K. M.; Hamilton, A; Kandel, D. B. (2016). "Birth Cohorts Analysis of Adolescent Cigarette Smoking and Subsequent Marijuana and Cocaine Use". American Journal of Public Health. 106 (6): 1143–9. doi:10.2105/AJPH.2016.303128. PMC   4880234 . PMID   27077359.
  40. ↑ Ren M, Lotfipour S (2019). "Nicotine Gateway Effects on Adolescent Substance Use". West J Emerg Med. 20 (5): 696–709. doi:10.5811/westjem.2019.7.41661. PMC   6754186 . PMID   31539325.
  41. ↑ Griffin EA, Melas PA, Zhou R, Li Y, Mercado P, Kempadoo KA (2017). "Prior alcohol use enhances vulnerability to compulsive cocaine self-administration by promoting degradation of HDAC4 and HDAC5". Sci Adv. 3 (11): e1701682. Bibcode:2017SciA....3E1682G. doi:10.1126/sciadv.1701682. PMC   5665598 . PMID   29109977.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  42. ↑ Anderson EM, Penrod RD, Barry SM, Hughes BW, Taniguchi M, Cowan CW (2019). "It is a complex issue: emerging connections between epigenetic regulators in drug addiction". Eur J Neurosci. 50 (3): 2477–2491. doi:10.1111/ejn.14170. PMID   30251397. S2CID   52816486.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  43. ↑ Lopez-Quintero C, Pérez de los Cobos J, Hasin DS, Okuda M, Wang S, Grant BF (2011). "Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC)". Drug Alcohol Depend. 115 (1–2): 120–30. doi:10.1016/j.drugalcdep.2010.11.004. PMC   3069146 . PMID   21145178.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  44. ↑ Bickel WK, Snider SE, Quisenberry AJ, Stein JS, Hanlon CA (2016). "Competing neurobehavioral decision systems theory of cocaine addiction: From mechanisms to therapeutic opportunities". Prog Brain Res. 223: 269–93. doi:10.1016/bs.pbr.2015.07.009. PMC   5495192 . PMID   26806781.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  45. ↑ Curran CP, Marczinski CA (2017). "Taurine, caffeine, and energy drinks: Reviewing the risks to the adolescent brain". Birth Defects Res. 109 (20): 1640–1648. doi:10.1002/bdr2.1177. PMC   5737830 . PMID   29251842.
  46. ↑ Arria AM, Caldeira KM, Kasperski SJ, O'Grady KE, Vincent KB, Griffiths RR (2010). "Increased alcohol consumption, nonmedical prescription drug use, and illicit drug use are associated with energy drink consumption among college students". J Addict Med. 4 (2): 74–80. doi:10.1097/ADM.0b013e3181aa8dd4. PMC   2923814 . PMID   20729975.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  47. ↑ Degenhardt, L; Dierker, L; Chiu, W. T.; Medina-Mora, M. E.; Neumark, Y; Sampson, N; Alonso, J; Angermeyer, M; Anthony, J. C.; Bruffaerts, R; De Girolamo, G; De Graaf, R; Gureje, O; Karam, A. N.; Kostyuchenko, S; Lee, S; Lépine, J. P.; Levinson, D; Nakamura, Y; Posada-Villa, J; Stein, D; Wells, J. E.; Kessler, R. C. (2010). "Evaluating the drug use "gateway" theory using cross-national data: Consistency and associations of the order of initiation of drug use among participants in the WHO World Mental Health Surveys". Drug and Alcohol Dependence. 108 (1–2): 84–97. doi:10.1016/j.drugalcdep.2009.12.001. PMC   2835832 . PMID   20060657.
  48. ↑ Stringer, S; Minică, C. C.; Verweij, K. J.; Mbarek, H; Bernard, M; Derringer, J; Van Eijk, K. R.; Isen, J. D.; Loukola, A; MacIejewski, D. F.; Mihailov, E; Van Der Most, P. J.; Sánchez-Mora, C; Roos, L; Sherva, R; Walters, R; Ware, J. J.; Abdellaoui, A; Bigdeli, T. B.; Branje, S. J.; Brown, S. A.; Bruinenberg, M; Casas, M; Esko, T; Garcia-Martinez, I; Gordon, S. D.; Harris, J. M.; Hartman, C. A.; Henders, A. K.; et al. (2016). "Genome-wide association study of lifetime cannabis use based on a large meta-analytic sample of 32 330 subjects from the International Cannabis Consortium". Translational Psychiatry. 6 (3): e769. doi:10.1038/tp.2016.36. PMC   4872459 . PMID   27023175.
  49. ↑ Lynskey, M. T.; Vink, J. M.; Boomsma, D. I. (2006). "Early onset cannabis use and progression to other drug use in a sample of Dutch twins". Behavior Genetics. 36 (2): 195–200. CiteSeerX   10.1.1.79.4510 . doi:10.1007/s10519-005-9023-x. PMID   16402286. S2CID   8263454., PDF Archived 2019-05-24 at the Wayback Machine
  50. 1 2 Agrawal A, Lynskey MT (2014). "Cannabis controversies: how genetics can inform the study of comorbidity". Addiction. 109 (3): 360–70. doi:10.1111/add.12436. PMC   3943474 . PMID   24438181. (Review).
  51. ↑ Cleveland, HH; Wiebe, RP (2008). "Understanding the association between adolescent marijuana use and later serious drug use: gateway effect or developmental trajectory?". Development and Psychopathology. 20 (2): 615–32. doi:10.1017/S0954579408000308. PMID   18423097. S2CID   19232946.

Further reading

Scientific textbooks

Lay scientific books

State of research before 1974

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.